1. Pacak K, Lenders JWM, Eisenhofer G. Introduction. In: pheochromocytoma diagnosis, localization and treatment. Malden, MA: Blackwell 2007; p. 1–2.
2. James A Lee, Rasa Zarnegar, Wen T et al. Adrenal Incidentaloma, Borderline Elevations of Urine or Plasma Metanephrine Levels, and the «Subclinical» Pheochromocytoma 2007 Arch Surg 2007; 142 (9): 870–4.
3. Kebebew E, Duh QY. Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-Up. Surg Oncol Clin N Am 1998; 7 (4): 765–89.
4. Manger WM, Eisenhofer G. Pheochromocytoma: Diagnosis and management update. Curr Hypertens Rep 2004; 6: 477–84.
5. Plouin PF, Degoulet P, Tugaye A et al. Screening for phaeochromocytoma: In which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma. Nouv Presse Med 1981; 10: 869–72.
6. Alderazi Y, Yeh MW, Robinson BG et al. Phaeochromocytoma: Current concepts. Med J Aust 2005; 183: 201–4.
7. Manger WM. An overview of pheochromocytoma: History, current concepts, vagaries, and diagnostic challenges. Ann NY Acad Sci 2006; 1073: 1–20.
8. Young WF, Jr, Maddox DE. Spells: In search of a cause. Mayo Clin Proc 1995; 70: 757–65.
9. Lenders JW, Sluiter HE, Thien T, Willemsen J. Treatment of a phaeochromocytoma of the urinary bladder with nifedipine. BMJ 1985; 290: 1624–5.
10. Bouloux PG, Fakeeh M. Investigation of phaeochromocytoma. Clin Endocrinol (Oxford) 1995; 43: 657–64.
11. Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens 2002; 4: 62–72.
12. Manger WM. The vagaries of pheochromocytomas. Am J Hypertens 2005; 18: 1266–70.
13. Barancik M. Inadvertent diagnosis of pheochromocytoma after endoscopic premedication. Dig Dis Sci 1989; 34: 136–8.
14. Bittar DA. Innovar-induced hypertensive crises in patients with pheochromocytoma. Anesthesiology 1979; 50: 366–9.
15. Cook RF, Katritsis D. Hypertensive crisis precipitated by a monoamine oxidase inhibitor in a patient with phaeochromocytoma. BMJ 1990; 300: 614–20.
16. Jan T, Metzger BE, Baumann G. Epinephrine-producing pheochromocytoma with hypertensive crisis after corticotropin injection. Am J Med 1990; 89: 824–5.
17. Page LB, Raker JW, Berberich FR. Pheochromocytoma with predominant epinephrine secretion. Am J Med 1969; 47: 648–52.
18. Schorr RT, Rogers SN. Intraoperative cardiovascular crisis caused by glucagon. Arch Surg 1987; 122: 833–4.
19. Steiner AL, Goodman AD, Powers SR. Study of a kindred with pheochromocytoma, medullary thyroid carcinoma, hyperparathyroidism and Cushing’s disease: multiple endocrine neoplasia, type 2. Medicine 1968; 47: 371–409.
20. Bravo EL, Gifford Jr. RW. Pheochromocytoma. Endocrinol Metab Clin North Am 1993; 22: 329–41.
21. Bravo EL, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003; 24: 539–53.
22. Дедов И.И., Бельцевич Д.Г., Кузнецов Н.С., Мельниченко Г.А. Феохромоцитома. М.: Практическая медицина, 2005.
23. Eisenhofer G, Walther MM, Huynh TT et al. Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 2001; 86: 1999–2008.
24. Kaltsas GA, Papadogias D, Makras P et al. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005; 12: 683–99.
25. Pacak K, Lenders JWM, Eisenhofer G. Catecholamines and adrenergic receptors. In: pheochromocytoma: diagnosis, localization and treatment. Malden, MA: Blackwell 2007; p. 41–71.
26. Brouwers FM, Gläsker S, Nave AF et al. Proteomic profiling of von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 pheochromocytomas reveals different expression of chromogranin B. Endocr Relat Cancer 2007; 14: 463–7.
27. Cleary S, Phillips JK, Huynh TT et al. Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome. J Endocrinol 2007; 193: 225–33.
28. Pacak K. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. HORMONES 2009; 8: 111–6.
29. Algeciras-Schimnich A, Preissner CM, Young WF et al. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. J Clin Endocrinol Metab 2008.
30. Harding JL, Yeh MW, Robinson BG et al. Potential pitfalls in the diagnosis of phaeochromocytoma. Med J Aust 2005; 182 (12): 637–40.
31. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069–79.
32. Pacak K, Lenders JWM, Eisenhofer G. Current trends in biochemical diagnosis of pheochromocytoma. In: pheochromocytoma, diagnosis, localization and treatment. Malden, MA: Blackwell 2007; p. 72–92.
33. Кузнецов Н.С., Гончаров Н.П., Кация Г.В. и др. Повышение уровня метилированных производных катехоламинов – патогномоничный лабораторный признак феохромоцитомы. Проблемы эндокринологии. 2007; 1: 33–6.
34. Lenders JW, Pacak K, Walther MM et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427–34.
35. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88 (10): 4533–9.
36. Giovanella L. Serum chromogranin-A assay in differential diagnosis of incidentally discovered adrenal masses. Anticancer Res 2005; 25: 1547–50.
37. Kinney MA, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 2002; 16: 359–69.
38. Bravo EL, Tarazi RC, Fouad FM et al. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. Jr N Engl J Med 1981; 305 (11): 623–6.
39. Elliott WJ, Murphy MB. Reduced specificity of the clonidine suppression test in patients with normal plasma catecholamine levels. 1988 Am J Med 84: 419–43.
40. Eisenhofer G, Goldstein DS, Walther MM et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656–6626.
41. Gross MD, Shapiro B, Sisson JC, Zweifler A. Clonidine-induced suppression of plasma catecholamines in states of adrenal medulla hyperfunction. J Endocrinol Invest 1987; 10 (4): 359–64.
42. Pacak K, Eisenhofer G, Ahlman H et al. Рheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab 2007; 3: 92–102.
43. Schutler J, Westhofen P, Kania U et al. Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery. Anasthesiol Intensivmed Notfallmed Schmerzther 1995; 30: 341–9.
44. Khorram-Manesh A, Ahlman H, Nilsson O et al. Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med 2005; 258: 55–66.
45. Plouin PF, Duclos JM, Soppelsa F et al. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: Analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001; 86: 1480–6.
46. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma-views on current management. Eur J Surg Oncol 2003; 29: 483–90.
47. Russell WJ, Metcalfe IR, Tonkin AL et al. The preoperative management of phaeochromocytoma. Anaesth Intensive Care 1998; 26: 196–200.
48. Mannelli M. Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 2006; 1073: 405–16.
49. Lebuffe G, Dosseh ED, Tek G et al. The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 2005; 60: 439–44.
50. Кузнецов Н.С., Бельцевич Д.Г., Лысенко М.А. Феохромоцитома. Русский врач. 2002; 7: 5–9.
51. Brogden RN, Heel RC, Speight TM et al. Methyl-p-tyrosine: A review of its pharmacology and clinical use. Drugs 1981; 21: 81–9.
52. Amar L, Servais A, Gimenez-Roqueplo AP et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 2005; 90: 2110–6.

Е.А.Трошина, М.Ю.Юкина, Д.Г.Бельцевич

ФГБУ Эндокринологический научный центр Минздрава РФ